"Dear Doctor Letter (Rote-Hand-Brief)
on GlucaGen® HypoKit (glucagon hydrochloride): Batch recall due to quality defect
Active substance glucagon hydrochloride
The company Novo Nordisk Pharma GmbH is circulating information that 3 batches of the GlucaGen® HypoKit are being recalled in Germany."
"Dear Doctor Letter (Rote-Hand-Brief) on Zydelig® (Idelalisib): Updated recommendations following conclusion of the safety data evaluation
Active substance idelalisib
The company Gilead Sciences GmbH is circulating information on the updated indication of idelalisib as first-line treatment of patients with chronic lymphocytic leukaemia (CLL) and on risk minimisation measures for prevention of infections."
"The January 2014 finalized guidance, Dear Health Care Providers: Improving Communication of Important Safety Information (Final Guidance), provides the U.S. Food and Drug Administration’s (FDA’s) recommendations on when manufacturers should issue a DHCP letter, as well as recommendations on the content and format of such letters. Also sometimes referred to as “Dear Doctor” letters, such communications are used by manufacturers to notify health care providers about new or updated information regarding a drug or biologic."